FMO5 and type 2 diabetes mellitus: Our previous work similarly demonstrated that sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors enabled glycemic control in type 2 diabetes mellitus (T2DM) patients, by downregulating RAGE-induced NADPH oxidase expression in LECs via the inactivation of GLUTs and reduced ROS generation [9].